Project Grant K22CA292451
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $157K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The U.S. National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Johns Hopkins University to conduct a comparative analysis of the effects of M-CSF and GM-CSF on human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The $162,486 award, effective from January 8, 2025 through August 31, 2027, aims to improve the understanding of how the cytokines M-CSF and GM-CSF differentially...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
- This $549,460 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida to study the role of the BCL11B transcription factor in regulating CD8+ T cell response and memory in tumor microenvironments. The award aims to establish the transcriptional programs and epigenomic landscape controlled by BCL11B in mouse T cells, with the goal of understanding...
- This federal Project Grant award of $344,111.00 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Loyola University of Chicago's Health Sciences Campus division. The grant supports research aimed at understanding the fundamental biological mechanisms of myelodysplastic syndromes (MDS), a group of bone marrow failure diseases that can transform into acute myeloid leukemia. The research focuses on targeting "panoptotic pathways" -...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) has awarded a $169,000 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of histone variant MacroH2A in shaping the tumor microenvironment and immune response in melanoma. The research aims to characterize how the loss of MacroH2A leads to increased activation and inflammatory gene expression in cancer-associated fibroblasts, and how this impacts tumor initiation and the anti-tumor...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- The U.S. National Cancer Institute (NCI) awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research to investigate the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion of triple negative breast cancer (TNBC). Specifically, the project aims to 1) elucidate the role of IFNγ in immune evasion during TNBC dissemination and metastatic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $173,500.00 to Health Research, Inc. to investigate the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma. The primary goal is to characterize the phenotype and transcriptional changes in myeloid cells in the tumor microenvironment of multiple myeloma patients, and to evaluate the efficacy of CXCR2 inhibitors in preclinical models. The...